Abstract
Background The Indian Biomedical Device Industry has been growing at an unprecedented rate, but several hindrances need to be acknowledged in offering access to quality, budget-friendly medical devices in India. This article explores the current loopholes of the Indian biomedical device industry along with the proposal of various innovative solutions, with emphasis on ventilators.
Methods An online survey with the help of Google forms was conducted from 1st November to 25th December 2020, addressing the problems of the Indian medical device industry (MDI) along with probable solutions. The survey also provides a glimpse into the complications aroused from the frequent use of ventilators during COVID-19 outburst, along with possible measures.
Results According to the survey, 51.6%, 46.5%, 55.7%, and 47.5% of respondents have agreed to ‘Stringent laws and implementation,’ ‘Safety testing and strict regulations,’ ‘Unfavorable duty structure,’ and ‘Reducing tax rate on domestic manufacturers,’ as a possible solution to advance the implementation of ISO 13485 and ISO 10651, implementation of ISO 14971, the probable cause of limitations of Indian MDI, possible measure to overcome limitations of Indian MDI, respectively. 46.7%, 47.5%, 46.2%, and 44.6% of respondents have agreed to ‘Surgical decompression,’ ‘Nebulized and broad-spectrum antibiotics,’ ‘PEEP,’ and ‘Adopting lung protective ventilation strategies’ as possible solutions to treat various ventilator complications, respectively.
Conclusion The study briefs about the people’s perception of the Indian MDI as well as on the ventilator complications. The results complied with our hypothesis as the majority of the respondents have agreed with almost all the probable solutions in both the sections given by us as options.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
None
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was exempted by the Indian Pharmacy Graduates' Association (Reg id: S/8255 of 1976) Ethics committee members: a) Mr. Atul Nasa, President, IPGA, Managing Trustee, IPGA Welfare Trust Deputy drugs controller with the charge of Controlling & Licensing Authority (CLA) at the drugs control department in Delhi government. b) Dr. Arun Garg, General Secretary, IPGA Dean, Institute of Pharmacy, NIMS University, Rajasthan c) Dr. Vijay Bhalla, Treasurer, IPGA Dean, SGT College of Pharmacy, SGT University, Haryana
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data available within the article or its supplementary materials
Abbreviations
- MDI
- Medical devices industry
- SARS-CoV-2
- Severe acute respiratory syndrome coronavirus 2 FDA-Food and Drug Administration
- EU
- European Union
- CE
- Conformité Européenne
- COVID-19
- Coronavirus disease 2019
- ISO
- International Organization for Standardization IT-Information Technology
- IIT
- Indian Institutes of Technology
- ARDS
- Acute respiratory distress syndrome CT-Computed tomography
- MDR
- Medical Device Reporting
- EMA
- European Medicines Agency US-United States
- QMS
- Quality management system Govt. – Government
- DCGI
- Drugs Controller General of India CL-Compulsory Licensing
- USFDA
- United States Food and Drug Administration COPD-Chronic Obstructive Pulmonary Disease
- ILD
- Interstitial Lung Disease
- ARDS
- Acute Respiratory Distress Syndrome AI-Artificial Intelligence
- VAP
- Ventilator-Associated Pneumonia ET-Endo-Tracheal Tube
- ICU
- Intensive Care Unit
- SSD
- Subglottic Secretion Drainage MDR-Multi-Drug Resistant
- PEEP
- Positive End-Expiratory Pressure PVC-Poly Vinyl Chloride
- MV
- Mechanical Ventilation
- VLI
- Ventilator-Induced Lung Injury
- NMBA
- Neuro-Muscular Blocking Agents RR-Respiratory Regulation
- ECMO
- Extra-Corporeal Membrane Oxygenation PP-Prone Positioning